羟考酮/纳洛酮:在慢性疼痛管理、阿片类药物引起的便秘和防止滥用中的作用。
Oxycodone/Naloxone: role in chronic pain management, opioid-induced constipation, and abuse deterrence.
机构信息
Aegis Sciences Corporation, Nashville, TN, USA,
出版信息
Pain Ther. 2014 Jun;3(1):1-15. doi: 10.1007/s40122-014-0026-2. Epub 2014 May 6.
The use of opioids in the treatment of chronic pain is widespread; the prevalence of specific opioids varies from country to country and depends on product availability, national formulary systems, and provider preferences. Patients often receive opioids for legitimate treatment of pain conditions, but on the opposite side of the spectrum, nonmedical use of opioids is a significant public health concern. Opioids are associated with several side effects, and constipation is the most commonly reported and persistent symptom. Unlike some adverse effects associated with opioid use, tolerance does not develop to constipation. Opioid-induced constipation (OIC) is the most prevalent patient complaint associated with opioid use and has been associated with declines in various quality of life measures. OIC can be extremely difficult for patients to tolerate and may prompt patients to decrease or discontinue opioid treatment. Current management strategies for OIC are often insufficient. A prolonged-release formulation of oxycodone/naloxone (OXN) has been investigated for the treatment of nonmalignant and cancer pain and mitigation of OIC, and evidence is largely favorable. Studies have demonstrated the capability of OXN to alleviate OIC while maintaining pain control comparable to oxycodone-only regimens. There is insufficient evidence for OXN efficacy for patients with mild OIC or patients maintained on high doses of opioids, and use in these populations is controversial. The reduction of costs associated with OIC may provide overall cost effectiveness with OXN. Additionally, the presence of naloxone may deter abuse/misuse by those seeking to misuse the formulation by modes of administration other than oral ingestion. Most studies to date have occurred in European countries, and phase 3 trials continue in the United States. This review will include current therapeutic options for pain and constipation, unique characteristics of OXN, evidence related to use of OXN and its place in therapy, discussion of opioid abuse/misuse, and various abuse-deterrent mechanisms, and areas of continuing research.
阿片类药物在慢性疼痛治疗中的应用非常广泛;特定阿片类药物的流行率因国家而异,取决于产品的可获得性、国家处方系统和提供者的偏好。患者通常因合法治疗疼痛病症而接受阿片类药物,但在另一方面,非医疗用途的阿片类药物是一个重大的公共卫生问题。阿片类药物与多种副作用相关,便秘是最常见和持续存在的症状。与使用阿片类药物相关的一些不良反应不同,对便秘不会产生耐受性。阿片类药物诱导的便秘(OIC)是与阿片类药物使用相关的最常见患者投诉,并与各种生活质量指标的下降相关。OIC 让患者非常难以忍受,可能促使患者减少或停止阿片类药物治疗。目前 OIC 的管理策略往往不够充分。阿片类药物/纳洛酮(OXN)的缓释制剂已被用于治疗非恶性和癌症疼痛以及减轻 OIC,并且证据主要是有利的。研究表明,OXN 能够缓解 OIC,同时保持与仅使用羟考酮方案相当的疼痛控制。对于轻度 OIC 患者或维持高剂量阿片类药物的患者,OXN 的疗效证据不足,并且在这些人群中的使用存在争议。与 OIC 相关的成本降低可能会使 OXN 具有总体成本效益。此外,纳洛酮的存在可能会阻止那些试图通过非口服摄入方式滥用/误用该制剂的人。迄今为止,大多数研究都发生在欧洲国家,美国的 3 期试验仍在继续。本综述将包括疼痛和便秘的当前治疗选择、OXN 的独特特征、与 OXN 使用及其在治疗中的地位相关的证据、阿片类药物滥用/误用的讨论以及各种防滥用机制,以及正在进行的研究领域。
相似文献
Expert Opin Pharmacother. 2019-1-9
引用本文的文献
J Res Pharm Pract. 2019
Curr Pain Headache Rep. 2018-4-4
Anaesthesist. 2017-11
Subst Abuse Rehabil. 2016-6-14
Clin Pharmacokinet. 2016-7
本文引用的文献
Curr Drug Targets. 2014-1